Regeneus Share Price and Company Fundamentals



Price
$0.105
Change
0.000 (0.000%)
52 week
0.059 - 0.2

Last traded: Today at 4:12 AM

Regeneus Ltd, a clinical-stage regenerative medicine company, engages in developing cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, and neuropathic pain and dermatology diseases. Its lead platform technology includes Progenza, a cryopreserved multi-synergistic therapy for the treatment of osteoarthritis and neuropathic pain. The company also develops Sygenus for the treatment of skin wound healing. Regeneus Ltd was founded in 2007 and is headquartered in Paddington, Australia.

Key Metrics

PE ratio

6.56

PB ratio

7.50

Dividend yield

Beta

0.20

Market cap

$31.53M

Enterprise value

$27.45M

Company profile

Primary activitiesRegenerative medicine.
Industry / SectorBiotechnology / Healthcare
Websitehttp://regeneus.com.au
Mailing address2 Paddington Street Paddington NSW 2021 Australia
Phone / Fax61 2 9499 8010 /
Share registryLINK MARKET SERVICES LIMITED

Dividends

Regeneus does not pay dividends.

Company Executives

As of May 2021, following are the company executives and directors listed on Regeneus.

NameTitleAgeTotal Pay
Prof. Graham Vesey Ph.D.Chief Scientific Officer & Exec. Director55171.34k
Mr. Karolis RosickasChief Exec. Officer
Dr. Charlotte Morgan Ph.D.Head of R&D

Profitability and management effectiveness

Profit margin

48.75%

Operating margin

59.24%

Return on assets

106.14%

Return on equity

236.09%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Regeneus is 31.53M and its enterprise value is 27.45M. The enterprise value to revenue ratio of RGS is 2.92.

The RGS's stocks Beta value is 0.20 making it 80% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Regeneus (RGS)

Regeneus (ASX:RGS) Frequently Asked Questions

1. What is Regeneus's Stock Symbol?

Regeneus trades on ASX under the ticker symbol "RGS".

2. What is Regeneus's stock price today?

One share of RGS stock can currently be purchased for approximately $0.105.

3. How can I contact Regeneus?

Regeneus's mailing address is 2 Paddington Street Paddington NSW 2021 Australia. The company can be reached via phone at 61 2 9499 8010.

4. What is Regeneus's official website?

The official website of Regeneus is http://regeneus.com.au.

5. Which share registry manages Regeneus's stock?

Regeneus's stock is managed by LINK MARKET SERVICES LIMITED.